An Orally Bioavailable Oxime Ether Capsid Binder with Potent Activity against Human Rhinovirus

An Orally Bioavailable Oxime Ether Capsid Binder with Potent Activity against Human Rhinovirus 2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsid binder 3-Aryl-1,2,4-oxadiazole Derivatives Active Against Human Rhinovirus An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus Synthesis and evaluation of novel chloropyridazine derivatives as potent human rhinovirus (HRV) capsid-binding inhibitors Synthesis of new compounds with promising antiviral properties against group A and B Human Rhinoviruses A model for compounds active against human rhinovirus-14 based on x-ray crystallography data Phenylpropenoids from <i>Bupleurum fruticosum</i> as Anti-Human Rhinovirus Species A Selective Capsid Binders VP1 crystal structure-guided exploration and optimization of 4,5-dimethoxybenzene-based inhibitors of rhinovirus 14 infection Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 8. Pharmacological Optimization of Orally Bioavailable 2-Pyridone-Containing Peptidomimetics